Off-Label Drug Lowers Relapses in Multiple Sclerosis

(MedPage Today) -- Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS), the phase III RIFUND-MS trial showed.
Relapses occurred in...